Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Walter RJ Taylor"'
Autor:
Sasithon Pukrittayakamee, Podjanee Jittamala, James A Watson, Borimas Hanboonkunupakarn, Pawanrat Leungsinsiri, Kittiyod Poovorawan, Kesinee Chotivanich, Germana Bancone, Cindy S Chu, Mallika Imwong, Nicholas PJ Day, Walter RJ Taylor, Nicholas J White
Publikováno v:
eLife, Vol 12 (2024)
Background: Primaquine is an 8-aminoquinoline antimalarial. It is the only widely available treatment to prevent relapses of Plasmodium vivax malaria. The 8-aminoquinolines cause dose-dependent haemolysis in glucose-6-phosphate dehydrogenase deficien
Externí odkaz:
https://doaj.org/article/e585cfc833ba4c7cb5854b2dab312fc7
Autor:
William HK Schilling, Podjanee Jittamala, James A Watson, Maneerat Ekkapongpisit, Tanaya Siripoon, Thundon Ngamprasertchai, Viravarn Luvira, Sasithorn Pongwilai, Cintia Cruz, James J Callery, Simon Boyd, Varaporn Kruabkontho, Thatsanun Ngernseng, Jaruwan Tubprasert, Mohammad Yazid Abdad, Nattaporn Piaraksa, Kanokon Suwannasin, Pongtorn Hanboonkunupakarn, Borimas Hanboonkunupakarn, Sakol Sookprome, Kittiyod Poovorawan, Janjira Thaipadungpanit, Stuart Blacksell, Mallika Imwong, Joel Tarning, Walter RJ Taylor, Vasin Chotivanich, Chunlanee Sangketchon, Wiroj Ruksakul, Kesinee Chotivanich, Mauro Martins Teixeira, Sasithon Pukrittayakamee, Arjen M Dondorp, Nicholas PJ Day, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Nicholas J White, on behalf of the PLATCOV Collaborative Group
Publikováno v:
eLife, Vol 12 (2023)
Background: There is no generally accepted methodology for in vivo assessment of antiviral activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment of COVID-19, but whether it has clinically significant antiviral activ
Externí odkaz:
https://doaj.org/article/e2c1da5e8a0a4bd4bce22cc5135ee7e1
Autor:
Xin Hui S Chan, Ilsa L Haeusler, Yan Naung Win, James Pike, Borimas Hanboonkunupakarn, Maryam Hanafiah, Sue J Lee, Abdoulaye Djimdé, Caterina I Fanello, Jean-René Kiechel, Marcus Vg Lacerda, Bernhards Ogutu, Marie A Onyamboko, André M Siqueira, Elizabeth A Ashley, Walter Rj Taylor, Nicholas J White
Publikováno v:
PLoS Medicine, Vol 18, Iss 9, p e1003766 (2021)
BackgroundAmodiaquine is a 4-aminoquinoline antimalarial similar to chloroquine that is used extensively for the treatment and prevention of malaria. Data on the cardiovascular effects of amodiaquine are scarce, although transient effects on cardiac
Externí odkaz:
https://doaj.org/article/9f5554785c2245449964647e4dd37413
Publikováno v:
eLife, Vol 6 (2017)
Primaquine is the only drug available to prevent relapse in vivax malaria. The main adverse effect of primaquine is erythrocyte age and dose-dependent acute haemolytic anaemia in individuals with glucose-6-phosphate dehydrogenase deficiency (G6PDd).
Externí odkaz:
https://doaj.org/article/fbce06d6e3984120bbc50dc0ceadc475
Autor:
Walter RJ Taylor, Dianne J Terlouw, Piero L Olliaro, Nicholas J White, Philippe Brasseur, Feiko O ter Kuile
Publikováno v:
Bulletin of the World Health Organization, Vol 84, Iss 12, Pp 956-964
OBJECTIVE: To test a novel methodology to define age-based dosing regimens for the treatment of malaria with a new, user-friendly, blister-packaged fixed-dose combination of artesunate and amodiaquine. METHODS: A weight-for-age reference database of
Externí odkaz:
https://doaj.org/article/6acf11ff96a34fd69ed88105148e200e
Autor:
Viravarn Luvira, William HK Schilling, Podjanee Jittamala, James A Watson, Simon Boyd, Tanaya Siripoon, Thundon Ngamprasertchai, Pedro J Almeida, Maneerat Ekkapongpisit, Cintia Cruz, James J Callery, Shivani Singh, Runch Tuntipaiboontana, Varaporn Kruabkontho, Thatsanun Ngernseng, Jaruwan Tubprasert, Mohammad Yazid Abdad, Srisuda Keayarsa, Wanassanan Madmanee, Renato S Aguiar, Franciele M Santos, Pongtorn Hanboonkunupakarn, Borimas Hanboonkunupakarn, Kittiyod Poovorawan, Mallika Imwong, Walter RJ Taylor, Vasin Chotivanich, Kesinee Chotivanich, Sasithon Pukrittayakamee, Arjen M Dondorp, Nicholas PJ Day, Mauro M Teixeira, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Nicholas J White
Background: Favipiravir, an anti-influenza drug, has in vitro antiviral activity against SARS-CoV-2. Clinical trial evidence to date is inconclusive. Favipiravir has been recommended for the treatment of COVID-19 in some countries. Methods: In a mult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::294a2d4e7c36d7423163dd0cc3a11e68
https://doi.org/10.21203/rs.3.rs-2675703/v1
https://doi.org/10.21203/rs.3.rs-2675703/v1
Autor:
Sasithon Pukrittayakamee, Podjanee Jittamala, James A Watson, Borimas Hanboonkunupakarn, Pawanrat Leungsinsiri, Kittiyod Poovorawan, Kesinee Chotivanich, Germana Bancone, Cindy S Chu, Mallika Imwong, Nicholas PJ Day, Walter RJ Taylor, Nicholas J White
BackgroundPrimaquine is the only widely available treatment to prevent relapses ofPlasmodium vivaxmalaria, but is underused because of concerns over haemolysis in glucose-6-phosphate dehydrogenase deficient (G6PDd) individuals. G6PDd is common in mal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3fe320c92f0b434846e930f3dcce5a3
https://doi.org/10.1101/2023.02.24.23286398
https://doi.org/10.1101/2023.02.24.23286398
Autor:
Podjanee Jittamala, William HK Schilling, James A Watson, Maneerat Ekkapongpisit, Tanaya Siripoon, Thundon Ngamprasertchai, Viravarn Luvira, Sasithorn Pongwilai, Cintia Cruz, James J Callery, Simon Boyd, Varaporn Kruabkontho, Thatsanun Ngernseng, Jaruwan Tubprasert, Mohammad Yazid Abdad, Nattaporn Piaraksa, Kanokon Suwannasin, Pongtorn Hanboonkunupakarn, Borimas Hanboonkunupakarn, Sakol Sookprome, Kittiyod Poovorawan, Janjira Thaipadungpanit, Stuart Blacksell, Mallika Imwong, Joel Tarning, Walter RJ Taylor, Vasin Chotivanich, Chunlanee Sangketchon, Wiroj Ruksakul, Kesinee Chotivanich, Mauro Martins Teixeira, Sasithon Pukrittayakamee, Arjen M Dondorp, Nicholas PJ Day, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Nicholas J White
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e105bed9e4ec73cec29958e1253201da
https://doi.org/10.7554/elife.83201.sa2
https://doi.org/10.7554/elife.83201.sa2
Autor:
Podjanee Jittamala, William HK Schilling, James A Watson, Viravarn Luvira, Tanaya Siripoon, Thundon Ngamprasertchai, Pedro J Almeida, Maneerat Ekkapongpisit, Cintia Cruz, James J Callery, Simon Boyd, Orawan Anunsittichai, Maliwan Hongsuwan, Yutatirat Singhaboot, Watcharee Pagornrat, Runch Tuntipaiboontana, Varaporn Kruabkontho, Thatsanun Ngernseng, Jaruwan Tubprasert, Mohammad Yazid Abdad, Srisuda Keayarsa, Wanassanan Madmanee, Renato S Aguiar, Franciele M Santos, Elizabeth M Batty, Pongtorn Hanboonkunupakarn, Borimas Hanboonkunupakarn, Sakol Sookprome, Kittiyod Poovorawan, Mallika Imwong, Walter RJ Taylor, Vasin Chotivanich, Chunlanee Sangketchon, Wiroj Ruksakul, Kesinee Chotivanich, Sasithon Pukrittayakamee, Arjen M Dondorp, Nicholas PJ Day, Mauro M Teixeira, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Nicholas J White
BackgroundUncertainty over the therapeutic benefit provided by parenteral remdesivir in COVID-19 has resulted in varying treatment guidelines. Early in the pandemic the monoclonal antibody cocktail, casirivimab/imdevimab, proved highly effective in c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f8b4bebb105cc4d47dea7ba7b07e50e
https://doi.org/10.1101/2022.10.17.22281161
https://doi.org/10.1101/2022.10.17.22281161
Autor:
William HK Schilling, Podjanee Jittamala, James A Watson, Maneerat Ekkapongpisit, Tanaya Siripoon, Thundon Ngamprasertchai, Viravarn Luvira, Sasithon Pongwilai, Cintia Cruz, James J Callery, Simon Boyd, Varaporn Kruabkontho, Thatsanun Ngernseng, Jaruwan Tubprasert, Mohammad Yazid Abdad, Nattaporn Piaraksa, Kanokon Suwannasin, Pongtorn Hanboonkunupakarn, Borimas Hanboonkunupakarn, Sakol Sookprome, Kittiyod Poovorawan, Janjira Thaipadungpanit, Stuart Blacksell, Mallika Imwong, Joel Tarning, Walter RJ Taylor, Vasin Chotivanich, Chunlanee Sangketchon, Wiroj Ruksakul, Kesinee Chotivanich, Mauro M Teixeira, Sasithon Pukrittayakamee, Arjen M Dondorp, Nicholas PJ Day, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Nicholas J White
BackgroundThere is no generally accepted methodology for in vivo assessment of antiviral activity in SARS-CoV-2 infection. Ivermectin has been recommended widely as a treatment of COVID-19, but whether it has significant antiviral activity in vivo is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab8c3280bf04937c7b5021965c4d3e2e
https://doi.org/10.1101/2022.07.15.22277570
https://doi.org/10.1101/2022.07.15.22277570